Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan, Lei Shura, Stephen Willingham, Maureen Howard, Susan Prohaska, Jens Volkmer, Mark Chao, Irving L Weissman, Ravindra Majeti, Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan, Lei Shura, Stephen Willingham, Maureen Howard, Susan Prohaska, Jens Volkmer, Mark Chao, Irving L Weissman, Ravindra Majeti
Abstract
CD47 is a widely expressed cell surface protein that functions as a regulator of phagocytosis mediated by cells of the innate immune system, such as macrophages and dendritic cells. CD47 serves as the ligand for a receptor on these innate immune cells, SIRP-alpha, which in turn delivers an inhibitory signal for phagocytosis. We previously found increased expression of CD47 on primary human acute myeloid leukemia (AML) stem cells, and demonstrated that blocking monoclonal antibodies directed against CD47 enabled the phagocytosis and elimination of AML, non-Hodgkin's lymphoma (NHL), and many solid tumors in xenograft models. Here, we report the development of a humanized anti-CD47 antibody with potent efficacy and favorable toxicokinetic properties as a candidate therapeutic. A novel monoclonal anti-human CD47 antibody, 5F9, was generated, and antibody humanization was carried out by grafting its complementarity determining regions (CDRs) onto a human IgG4 format. The resulting humanized 5F9 antibody (Hu5F9-G4) bound monomeric human CD47 with an 8 nM affinity. Hu5F9-G4 induced potent macrophage-mediated phagocytosis of primary human AML cells in vitro and completely eradicated human AML in vivo, leading to long-term disease-free survival of patient-derived xenografts. Moreover, Hu5F9-G4 synergized with rituximab to eliminate NHL engraftment and cure xenografted mice. Finally, toxicokinetic studies in non-human primates showed that Hu5F9-G4 could be safely administered intravenously at doses able to achieve potentially therapeutic serum levels. Thus, Hu5F9-G4 is actively being developed for and has been entered into clinical trials in patients with AML and solid tumors (ClinicalTrials.gov identifier: NCT02216409).
Conflict of interest statement
Competing Interests: JL, RM, and ILW have filed International Patent Application WO 2011/143624 A2 entitled ‘Humanized and chimeric monoclonal antibodies to CD47’. JL, RM, ILW, SW, JV, MH, and SP have filed U.S. Patent Application number PCT/US2014/018743 entitled ‘Methods for achieving therapeutically effective doses of anti-CD47 agents’. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674. 10.1016/j.cell.2011.02.013
- Chao MP, Majeti R, Weissman IL (2012) Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 12: 58–67.
- Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. (2010) Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. Science Translational Medicine 2.
- Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894–1907.
- Lowenberg B, Downing JR, Burnett A (1999) Medical progress—Acute myeloid leukemia. New England Journal of Medicine 341: 1051–1062.
- Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. (2009) CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Cell 138: 286–299. 10.1016/j.cell.2009.05.045
- Majeti R, Chao MP, Alizadeh AA, Pang WW, Weissman IL (2008) CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Blood 112: 284–284.
- Jordan CT, Guzman ML, Noble M (2006) Mechanisms of disease—Cancer stem cells. New England Journal of Medicine 355: 1253–1261.
- Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111.
- Majeti R (2010) Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells oncogene 1.
- Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends in Cell Biology 11: 130–135.
- Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. (2009) CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. Cell 138: 271–285. 10.1016/j.cell.2009.05.046
- Barclay AN, Brown MH (2006) The SIRP family of receptors and immune regulation. Nature Reviews Immunology 6: 457–464.
- Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Lizuka K, et al. (2001) CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. Journal of Experimental Medicine 194: 541–549.
- Okazawa H, Motegi SI, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, et al. (2005) Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. Journal of Immunology 174: 2004–2011.
- Oldenborg PA, Gresham HD, Lindberg FP (2001) CD47-signal regulatory protein alpha (SIRP alpha) regulates Fc gamma and complement receptor-mediated phagocytosis. Journal of Experimental Medicine 193: 855–861.
- Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. (2000) Role of CD47 as a marker of self on red blood cells. Science 288: 2051–2054.
- Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, et al. (2005) Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 174: 2004–2011.
- Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, et al. (1996) A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol 16: 6887–6899.
- Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. (1997) A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386: 181–186.
- Timms JF, Carlberg K, Gu H, Chen H, Kamatkar S, Nadler MJ, et al. (1998) Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages. Mol Cell Biol 18: 3838–3850.
- Tsai RK, Discher DE (2008) Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180: 989–1003. 10.1083/jcb.200708043
- Oldenborg PA (2004) Role of CD47 in erythroid cells and in autoimmunity. Leuk Lymphoma 45: 1319–1327.
- Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212–219. 10.1016/j.it.2010.04.001
- Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699–713. 10.1016/j.cell.2010.07.044
- Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109: 6662–6667. 10.1073/pnas.1121623109
- Chao MP, Alizadeh AA, Tang CZ, Myklebust JH, Varghese B, Jan M, et al. (2009) Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. Blood 114: 1063–1064.
- Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374–1384. 10.1158/0008-5472.CAN-10-2238
- Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 109: 6656–6661. 10.1073/pnas.1121629109
- Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26: 2538–2545. 10.1038/leu.2012.141
- Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. (1989) A Humanized Antibody That Binds to the Interleukin-2 Receptor. Proceedings of the National Academy of Sciences of the United States of America 86: 10029–10033.
- Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. (1993) A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30: 105–108.
- Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY (1997) Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 6: 407–415.
- Schuurman J, Perdok GJ, Gorter AD, Aalberse RC (2001) The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 38: 1–8.
- Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y, et al. (2005) Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29: 445–450.
- Kikuchi Y, Uno S, Yoshimura Y, Otabe K, Iida S, Oheda M, et al. (2004) A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells. Biochem Biophys Res Commun 315: 912–918.
- Mateo V, Lagneaux L, Bron D, Biron G, Armant M, Delespesse G, et al. (1999) CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 5: 1277–1284.
- Uno S, Kinoshita Y, Azuma Y, Tsunenari T, Yoshimura Y, Iida S, et al. (2007) Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol Rep 17: 1189–1194.
- Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. (2008) Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell 31: 266–277. 10.1016/j.molcel.2008.05.026
- Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24: 225–232. 10.1016/j.coi.2012.01.010
- Soto-Pantoja DR, Miller TW, Frazier WA, Roberts DD (2012) Inhibitory signaling through signal regulatory protein-alpha is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci U S A 109: E2842; author reply E2844–2845. 10.1073/pnas.1205441109
- Kim MJ, Lee JC, Lee JJ, Kim S, Lee SG, Park SW, et al. (2008) Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 29: 28–34. 10.1159/000132568
- Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, et al. (2011) CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 108: 18342–18347. 10.1073/pnas.1106550108
- Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9: 457–492.
- Antonelou MH, Kriebardis AG, Papassideri IS (2010) Aging and death signalling in mature red cells: from basic science to transfusion practice. Blood Transfus 8 Suppl 3: s39–47. 10.2450/2010.007S
- Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R (2012) CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 119: 5512–5521. 10.1182/blood-2011-10-386805
- van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, et al. (2013) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 5: 810–816. 10.4161/mabs.25234
Source: PubMed